167 related articles for article (PubMed ID: 25126591)
41. Molecular genetics of osteosarcoma.
Rickel K; Fang F; Tao J
Bone; 2017 Sep; 102():69-79. PubMed ID: 27760307
[TBL] [Abstract][Full Text] [Related]
42. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
43. Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors.
Wheler JJ; Atkins JT; Janku F; Moulder SL; Stephens PJ; Yelensky R; Valero V; Miller V; Kurzrock R; Meric-Bernstam F
Oncoscience; 2016; 3(5-6):164-72. PubMed ID: 27489863
[TBL] [Abstract][Full Text] [Related]
44. The genetic basis for inactivation of Wnt pathway in human osteosarcoma.
Du X; Yang J; Yang D; Tian W; Zhu Z
BMC Cancer; 2014 Jun; 14():450. PubMed ID: 24942472
[TBL] [Abstract][Full Text] [Related]
45. Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma.
Bishop MW; Janeway KA
F1000Res; 2016; 5():. PubMed ID: 27441088
[TBL] [Abstract][Full Text] [Related]
46. Genetic and molecular characterization of the human osteosarcoma 3AB-OS cancer stem cell line: a possible model for studying osteosarcoma origin and stemness.
Di Fiore R; Fanale D; Drago-Ferrante R; Chiaradonna F; Giuliano M; De Blasio A; Amodeo V; Corsini LR; Bazan V; Tesoriere G; Vento R; Russo A
J Cell Physiol; 2013 Jun; 228(6):1189-201. PubMed ID: 23129384
[TBL] [Abstract][Full Text] [Related]
47. HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors.
Dailey DD; Anfinsen KP; Pfaff LE; Ehrhart EJ; Charles JB; Bønsdorff TB; Thamm DH; Powers BE; Jonasdottir TJ; Duval DL
BMC Vet Res; 2013 Jul; 9():130. PubMed ID: 23816051
[TBL] [Abstract][Full Text] [Related]
48. Genomic Complexity of Osteosarcoma and Its Implication for Preclinical and Clinical Targeted Therapies.
Schott C; Shah AT; Sweet-Cordero EA
Adv Exp Med Biol; 2020; 1258():1-19. PubMed ID: 32767231
[TBL] [Abstract][Full Text] [Related]
49. Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.
Ross DS; Zehir A; Cheng DT; Benayed R; Nafa K; Hechtman JF; Janjigian YY; Weigelt B; Razavi P; Hyman DM; Baselga J; Berger MF; Ladanyi M; Arcila ME
J Mol Diagn; 2017 Mar; 19(2):244-254. PubMed ID: 28027945
[TBL] [Abstract][Full Text] [Related]
50. Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma.
Maire G; Martin JW; Yoshimoto M; Chilton-MacNeill S; Zielenska M; Squire JA
Cancer Genet; 2011 Mar; 204(3):138-46. PubMed ID: 21504713
[TBL] [Abstract][Full Text] [Related]
51. The possibility of clinical sequencing in the management of cancer.
Kou T; Kanai M; Matsumoto S; Okuno Y; Muto M
Jpn J Clin Oncol; 2016 May; 46(5):399-406. PubMed ID: 26917600
[TBL] [Abstract][Full Text] [Related]
52. Genomics and the Immune Landscape of Osteosarcoma.
Wu CC; Livingston JA
Adv Exp Med Biol; 2020; 1258():21-36. PubMed ID: 32767232
[TBL] [Abstract][Full Text] [Related]
53. Molecular variations in uterine carcinosarcomas identify therapeutic opportunities.
Crane E; Naumann W; Tait D; Higgins R; Herzog T; Brown J
Int J Gynecol Cancer; 2020 Apr; 30(4):480-484. PubMed ID: 32114514
[TBL] [Abstract][Full Text] [Related]
54. Applied precision cancer medicine in metastatic biliary tract cancer.
Taghizadeh H; Müllauer L; Mader R; Prager GW
Hepatol Int; 2020 Mar; 14(2):288-295. PubMed ID: 32100259
[TBL] [Abstract][Full Text] [Related]
55. Understanding the Osteosarcoma Pathobiology: A Comparative Oncology Approach.
Varshney J; Scott MC; Largaespada DA; Subramanian S
Vet Sci; 2016 Jan; 3(1):. PubMed ID: 29056713
[TBL] [Abstract][Full Text] [Related]
56. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma.
Man TK; Lu XY; Jaeweon K; Perlaky L; Harris CP; Shah S; Ladanyi M; Gorlick R; Lau CC; Rao PH
BMC Cancer; 2004 Aug; 4():45. PubMed ID: 15298715
[TBL] [Abstract][Full Text] [Related]
57. Characterization of canine osteosarcoma by array comparative genomic hybridization and RT-qPCR: signatures of genomic imbalance in canine osteosarcoma parallel the human counterpart.
Angstadt AY; Motsinger-Reif A; Thomas R; Kisseberth WC; Guillermo Couto C; Duval DL; Nielsen DM; Modiano JF; Breen M
Genes Chromosomes Cancer; 2011 Nov; 50(11):859-74. PubMed ID: 21837709
[TBL] [Abstract][Full Text] [Related]
58. Mechanism of miR-122-5p regulating the activation of PI3K-Akt-mTOR signaling pathway on the cell proliferation and apoptosis of osteosarcoma cells through targeting TP53 gene.
Li KW; Wang SH; Wei X; Hou YZ; Li ZH
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12655-12666. PubMed ID: 33378012
[TBL] [Abstract][Full Text] [Related]
59. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
Tetzlaff MT; Singh RR; Seviour EG; Curry JL; Hudgens CW; Bell D; Wimmer DA; Ning J; Czerniak BA; Zhang L; Davies MA; Prieto VG; Broaddus RR; Ram P; Luthra R; Esmaeli B
J Pathol; 2016 Sep; 240(1):84-95. PubMed ID: 27287813
[TBL] [Abstract][Full Text] [Related]
60. MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines.
Fenger JM; Roberts RD; Iwenofu OH; Bear MD; Zhang X; Couto JI; Modiano JF; Kisseberth WC; London CA
BMC Cancer; 2016 Oct; 16(1):784. PubMed ID: 27724924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
